151 related articles for article (PubMed ID: 23474128)
1. K-ras 4A and 4B mRNA levels correlate with superoxide in lung adenocarcinoma cells, while at the protein level, only mutant K-ras 4A protein correlates with superoxide.
Calvert RJ; Gupta M; Maciag A; Shiao YH; Anderson LM
Lung Cancer; 2013 Jun; 80(3):263-9. PubMed ID: 23474128
[TBL] [Abstract][Full Text] [Related]
2. The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the ApcMin/+ mouse small intestine.
Patek CE; Arends MJ; Rose L; Luo F; Walker M; Devenney PS; Berry RL; Lawrence NJ; Ridgway RA; Sansom OJ; Hooper ML
BMC Gastroenterol; 2008 Jun; 8():24. PubMed ID: 18554389
[TBL] [Abstract][Full Text] [Related]
3. K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer.
Plowman SJ; Berry RL; Bader SA; Luo F; Arends MJ; Harrison DJ; Hooper ML; Patek CE
J Exp Clin Cancer Res; 2006 Jun; 25(2):259-67. PubMed ID: 16918139
[TBL] [Abstract][Full Text] [Related]
4. Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis.
Patek CE; Arends MJ; Wallace WA; Luo F; Hagan S; Brownstein DG; Rose L; Devenney PS; Walker M; Plowman SJ; Berry RL; Kolch W; Sansom OJ; Harrison DJ; Hooper ML
Exp Cell Res; 2008 Mar; 314(5):1105-14. PubMed ID: 18062963
[TBL] [Abstract][Full Text] [Related]
5. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
[TBL] [Abstract][Full Text] [Related]
6. K-ras p21 expression and activity in lung and lung tumors.
Ramakrishna G; Sithanandam G; Cheng RY; Fornwald LW; Smith GT; Diwan BA; Anderson LM
Exp Lung Res; 2000 Dec; 26(8):659-71. PubMed ID: 11195463
[TBL] [Abstract][Full Text] [Related]
7. Sirt1 protects from K-Ras-driven lung carcinogenesis.
Costa-Machado LF; Martín-Hernández R; Sanchez-Luengo MÁ; Hess K; Vales-Villamarin C; Barradas M; Lynch C; de la Nava D; Diaz-Ruiz A; de Cabo R; Cañamero M; Martinez L; Sanchez-Carbayo M; Herranz D; Serrano M; Fernandez-Marcos PJ
EMBO Rep; 2018 Sep; 19(9):. PubMed ID: 30021836
[TBL] [Abstract][Full Text] [Related]
8. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
Volonte D; Vyas AR; Chen C; Dacic S; Stabile LP; Kurland BF; Abberbock SR; Burns TF; Herman JG; Di YP; Galbiati F
J Biol Chem; 2018 Feb; 293(5):1794-1809. PubMed ID: 29247004
[TBL] [Abstract][Full Text] [Related]
9. DNA damage, superoxide, and mutant K-ras in human lung adenocarcinoma cells.
Romanowska M; Maciag A; Smith AL; Fields JR; Fornwald LW; Kikawa KD; Kasprzak KS; Anderson LM
Free Radic Biol Med; 2007 Oct; 43(8):1145-55. PubMed ID: 17854710
[TBL] [Abstract][Full Text] [Related]
10. Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.
Pan Y; Jiang Y; Tan L; Ravoori MK; Gagea M; Kundra V; Fischer SM; Yang P
Oncotarget; 2015 Nov; 6(36):38816-26. PubMed ID: 26452035
[TBL] [Abstract][Full Text] [Related]
11. K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation.
Luo F; Ye H; Hamoudi R; Dong G; Zhang W; Patek CE; Poulogiannis G; Arends MJ
J Pathol; 2010 Apr; 220(5):542-50. PubMed ID: 20087880
[TBL] [Abstract][Full Text] [Related]
12. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma.
Xu X; Rock JR; Lu Y; Futtner C; Schwab B; Guinney J; Hogan BL; Onaitis MW
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):4910-5. PubMed ID: 22411819
[TBL] [Abstract][Full Text] [Related]
13. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma.
Lee YS; Lee JW; Jang JW; Chi XZ; Kim JH; Li YH; Kim MK; Kim DM; Choi BS; Kim EG; Chung JH; Lee OJ; Lee YM; Suh JW; Chuang LS; Ito Y; Bae SC
Cancer Cell; 2013 Nov; 24(5):603-16. PubMed ID: 24229708
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung.
Nemunaitis J; Klemow S; Tong A; Courtney A; Johnston W; Mack M; Taylor W; Solano M; Stone M; Mallams J; Mues G
Am J Clin Oncol; 1998 Apr; 21(2):155-60. PubMed ID: 9537203
[TBL] [Abstract][Full Text] [Related]
15. A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.
Aran V; Masson Domingues P; Carvalho de Macedo F; Moreira de Sousa CA; Caldas Montella T; de Souza Accioly MT; Ferreira CG
Lung Cancer; 2018 Feb; 116():7-14. PubMed ID: 29413054
[TBL] [Abstract][Full Text] [Related]
16.
Lee YS; Lee JY; Song SH; Kim DM; Lee JW; Chi XZ; Ito Y; Bae SC
Mol Cells; 2020 Oct; 43(10):889-897. PubMed ID: 33115981
[No Abstract] [Full Text] [Related]
17. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.
Sutherland KD; Song JY; Kwon MC; Proost N; Zevenhoven J; Berns A
Proc Natl Acad Sci U S A; 2014 Apr; 111(13):4952-7. PubMed ID: 24586047
[TBL] [Abstract][Full Text] [Related]
18. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.
Elad G; Paz A; Haklai R; Marciano D; Cox A; Kloog Y
Biochim Biophys Acta; 1999 Dec; 1452(3):228-42. PubMed ID: 10590312
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
20. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Ohm AM; Tan AC; Heasley LE; Reyland ME
Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
